Mereo BioPharma Group plc (MREO)

Market Cap	518.91M
Revenue (ttm)	1,000,000
Net Income (ttm)	-45.32M
Shares Out	154.90M
EPS (ttm)	-0.31
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	1,762,229
Open	3.280
Previous Close	3.290
Day's Range	3.110 - 3.390
52-Week Range	2.030 - 5.020
Beta	0.91
Analysts	Strong Buy
Price Target	7.40 (+120.9%)
Earnings Date	Feb 13, 2025

About MREO

Mereo BioPharma Group plc, a biopharmaceutical company, develops and commercializes therapeutics for the treatment of oncology and rare diseases in the United Kingdom, the United States, and internationally. It develops Etigilimab (MPH-313), an antibody T-cell immunoreceptor with Ig and ITIM domains, which is in Phase 1b clinical trial for the treatment of tumors. The company is also developing Navicixizumab (OMP-305B83), which has completed Phase 1b clinical trials for the treatment of the late line ovarian cancer; Acumapimod (BCT-197), a p38 ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2015
• Employees: 33
• Stock Exchange: NASDAQ
• Ticker Symbol: MREO
• Website: https://www.mereobiopharma.com

Analyst Forecast

According to 5 analysts, the average rating for MREO stock is "Strong Buy." The 12-month stock price forecast is $7.4, which is an increase of 120.90% from the latest price.

Price Target

$7.4

(120.90% upside)

Analyst Consensus: Strong Buy